Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 |
| NCT01169350 | 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02113826 | Pazopanib for Metastatic Alveolar Soft Part Sarcoma | terminated | Phase 2 | 6 | Seoul National University HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | unknown | Phase 2 | 60 | Assaf-Harofeh Medical CenterOTHER_GOV | 0 | Nov 1, 2017 | clinicaltrials |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02342600 | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | withdrawn | Phase 2 | 0 | Sarcoma Alliance for Research through CollaborationOTHER | 0 | Oct 12, 2017 | clinicaltrials |
| NCT00003521 | Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma | terminated | Phase 2 | 14 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00055237 | Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01055314 | Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma | completed | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 4 | Aug 29, 2017 | clinicaltrials |
| NCT03149120 | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01861951 | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma(EPAZ) | completed | Phase 2 | 120 | Hannover Medical SchoolOTHER | 2 | Aug 21, 2017 | clinicaltrials |
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT00332033 | Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) | completed | Phase 2 | 32 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00633295 | Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT03171389 | POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST(POETIG) | unknown | Phase 2 | 81 | Sebastian BauerOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT03121846 | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy | unknown | Phase 2 | 80 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 22, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00045734 | Imatinib Mesylate in Treating Patients With Recurrent Meningioma | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 15, 2017 | clinicaltrials |
| NCT01524848 | Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib(PAGIST) | completed | Phase 2 | 72 | Scandinavian Sarcoma GroupOTHER | 5 | May 10, 2017 | clinicaltrials |
| NCT01222715 | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 4 | May 5, 2017 | clinicaltrials |
| NCT01137916 | Study to Evaluate Imatinib in Desmoid Tumors | completed | Phase 2 | 39 | Heidelberg UniversityOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00413192 | E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 128 | Eisai Inc.INDUSTRY | 5 | Apr 26, 2017 | clinicaltrials |
| NCT02449343 | Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203) | unknown | Phase 2 / Phase 3 | 233 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00978146 | Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors | withdrawn | Phase 2 | 0 | Children's Hospital of PhiladelphiaOTHER | 0 | Apr 20, 2017 | clinicaltrials |
| NCT01259375 | Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma(ARSARC-PI-0010) | completed | Phase 2 | 24 | University of UtahOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01185964 | A Study of Olaratumab in Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 148 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 2 | 25 | Kristen GanjooOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT00365872 | External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01089595 | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 2 | 5 | Fox Chase Cancer CenterOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT01110668 | Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | completed | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT03064243 | A Phase II Study of Apatinib in STS Patients | unknown | Phase 2 | 53 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 0 | Feb 27, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00718562 | Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib | completed | Phase 2 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00585221 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00881595 | Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas(SA02) | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | Feb 10, 2017 | clinicaltrials |
| NCT00031629 | Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Dec 8, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02571829 | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Hadassah Medical OrganizationOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT01483014 | Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)(CONVERT) | completed | Phase 2 | 30 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 18, 2016 | clinicaltrials |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | terminated | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 9, 2016 | clinicaltrials |
| NCT00563680 | QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors | completed | Phase 2 | 38 | NantCell, Inc.INDUSTRY | 0 | Oct 27, 2016 | clinicaltrials |
| NCT02367651 | Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Oct 12, 2016 | clinicaltrials |
| NCT01404650 | Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor | completed | Phase 2 | 25 | SCRI Development Innovations, LLCOTHER | 1 | Oct 4, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 7, 2017source: clinicaltrials